Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 127.15% ano a ano.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 5.07M.
Sobreavaliada
O PE mais recente da empresa é -0.09, em uma faixa percentil alta de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 494.53K ações, uma redução de 27.86% em relação ao trimestre anterior.